Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston's "third-gen" drug-eluting stent reaches Europe

This article was originally published in Clinica

Executive Summary

Boston Scientific has CE marked Promus Element, its "third-generation" everolimus-eluting stent, for sale in Europe. It is made of a platinum chromium alloy, which offers greater radial strength and flexibility than older alloys such as cobalt chromium, the Natick, Massachusetts firm claims. Boston will begin marketing the device immediately in the EU and other CE mark countries. Promus Element is being evaluated in the 1,532-patient PLATINUM clinical trial, designed to support its US and Japanese approval. US FDA approval is expected in 2012. A trial of Boston's paclitaxel-eluting Taxus Element stent, which also employs the platinum chromium alloy, is due to report primary endpoint data in March 2010. CE marking of Taxus Element is expected in the second quarter of 2010, with FDA approval due to follow in 2011.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts